Kusaka Sachie, Morizane Yuri, Tokumaru Yugo, Tamaki Shingo, Maemunah Indah Rosidah, Akiyama Yoko, Sato Fuminobu, Murata Isao
Division of Sustainable Energy and Environmental Engineering, Graduate School of Engineering, Osaka University, Yamadaoka 2-1, Suita 565-0871, Osaka, Japan.
Biology (Basel). 2022 Mar 3;11(3):397. doi: 10.3390/biology11030397.
Recently, exploitation of cerebrospinal fluid (CSF) circulation has become increasingly recognized as a feasible strategy to solve the challenges involved in drug delivery for treating brain tumors. Boron neutron capture therapy (BNCT) also faces challenges associated with the development of an efficient delivery system for boron, especially to brain tumors. Our laboratory has been developing a system for boron delivery to brain cells using CSF, which we call the "boron CSF administration method". In our previous study, we found that boron was efficiently delivered to the brain cells of normal rats in the form of small amounts of L-p-boronophenylalanine (BPA) using the CSF administration method. In the study described here, we carried out experiments with brain tumor model rats to demonstrate the usefulness of the CSF administration method for BNCT. We first investigated the boron concentration of the brain cells every 60 min after BPA administration into the lateral ventricle of normal rats. Second, we measured and compared the boron concentration in the melanoma model rats after administering boron via either the CSF administration method or the intravenous (IV) administration method, with estimation of the T/N ratio. Our results revealed that boron injected by the CSF administration method was excreted quickly from normal cells, resulting in a high T/N ratio compared to that of IV administration. In addition, the CSF administration method resulted in high boron accumulation in tumor cells. In conclusion, we found that using our developed CSF administration method results in more selective delivery of boron to the brain tumor compared with the IV administration method.
最近,利用脑脊液(CSF)循环作为一种可行策略来解决脑肿瘤治疗中药物递送所涉及的挑战,这一点已得到越来越多的认可。硼中子俘获疗法(BNCT)在开发高效的硼递送系统(尤其是针对脑肿瘤的系统)方面也面临挑战。我们实验室一直在研发一种利用脑脊液将硼递送至脑细胞的系统,我们称之为“脑脊液硼给药法”。在我们之前的研究中,我们发现使用脑脊液给药法,硼能够以少量L - 对硼苯丙氨酸(BPA)的形式有效地递送至正常大鼠的脑细胞。在此处描述的研究中,我们对脑肿瘤模型大鼠进行了实验,以证明脑脊液给药法对BNCT的有效性。我们首先在将BPA注入正常大鼠侧脑室后,每隔60分钟检测一次脑细胞中的硼浓度。其次,我们在通过脑脊液给药法或静脉内(IV)给药法给予硼后,测量并比较黑色素瘤模型大鼠中的硼浓度,并估算T/N比。我们的结果显示,通过脑脊液给药法注入的硼从正常细胞中排泄迅速,与静脉内给药相比,T/N比更高。此外,脑脊液给药法导致肿瘤细胞中硼的高积累。总之,我们发现与静脉内给药法相比,使用我们开发的脑脊液给药法可使硼更具选择性地递送至脑肿瘤。